Your browser doesn't support javascript.
Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan.
Chang, Jer-Hwa; Chiou, Jeng-Fong; Hung, Ching-Sheng; Liu, Ming-Che; Chang, Hui-Wen; Hong, Shiao-Ya; Wang, Cheng-Yi; Lin, Yi-Ling; Hsieh, Yi-Chen; Chung, Chi-Li; Su, Ying-Shih; Hsiao, Shu-Tai Shen; Liu, Doresses; Liang, Jian-Jong; Liao, Chun-Che; Chang, Chih-Shin; Lai, Kevin Shu-Leung; Chuang, Han-Chuan; Chien, Ko-Ling; Wu, Wei-Ciao; Lee, Yuan-Chii G; Lin, Sey-En; Shen, Yung-Kang; Hsu, Chiung-Fang; Wang, Jude Chu-Chun; Hsiao, Shih-Hsin.
  • Chang JH; School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Chiou JF; Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
  • Hung CS; Department of Radiation Oncology, Taipei Medical University Hospital, Taipei 11031, Taiwan.
  • Liu MC; Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Chang HW; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
  • Hong SY; Department of Laboratory Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
  • Wang CY; Department of Urology, Taipei Medical University Hospital, Taipei 11031, Taiwan.
  • Lin YL; School of Dental Technology, College of Oral Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Hsieh YC; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
  • Chung CL; Department of Medical Laboratory, Taipei Medical University Hospital, Taipei 11031, Taiwan.
  • Su YS; Medical Research Center, Cardinal Tien Hospital, New Taipei 24148, Taiwan.
  • Hsiao SS; Department of Internal Medicine, Cardinal Tien Hospital, New Taipei 23148, Taiwan.
  • Liu D; School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei 24205, Taiwan.
  • Liang JJ; Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.
  • Liao CC; Biomedical Translation Research Center, Academia Sinica, Taipei 11529, Taiwan.
  • Chang CS; Ph.D. Program of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
  • Lai KS; Master Program in Applied Molecular Epidemiology, College of Public Health, Taipei Medical University, Taipei 11031, Taiwan.
  • Chuang HC; Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Chien KL; Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan.
  • Wu WC; Division of Infectious Disease, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
  • Lee YG; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Lin SE; Department of Nursing, Taipei Medical University Hospital, Taipei 11031, Taiwan.
  • Shen YK; School of Nursing, College of Nursing, Taipei Medical University, Taipei 11031, Taiwan.
  • Hsu CF; Department of Nursing, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
  • Wang JC; Center for Nursing and Healthcare Research in Clinical Practice Application, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
  • Hsiao SH; Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.
Vaccines (Basel) ; 10(2)2022 Feb 17.
Article in English | MEDLINE | ID: covidwho-1708024
ABSTRACT

BACKGROUND:

The ChAdOx1 nCoV-19 vaccine has been widely administered against SARS-CoV-2 infection; however, data regarding its immunogenicity, reactogenicity, and potential differences in responses among Asian populations remain scarce.

METHODS:

270 participants without prior COVID-19 were enrolled to receive ChAdOx1 nCoV-19 vaccination with a prime-boost interval of 8-9 weeks. Their specific SARS-CoV-2 antibodies, neutralizing antibody titers (NT50), platelet counts, and D-dimer levels were analyzed before and after vaccination.

RESULTS:

The seroconversion rates of anti-RBD and anti-spike IgG at day 28 after a boost vaccination (BD28) were 100% and 95.19%, respectively. Anti-RBD and anti-spike IgG levels were highly correlated (r = 0.7891), which were 172.9 ± 170.4 and 179.3 ± 76.88 BAU/mL at BD28, respectively. The geometric mean concentrations (GMCs) of NT50 for all participants increased to 132.9 IU/mL (95% CI 120.0-147.1) at BD28 and were highly correlated with anti-RBD and anti-spike IgG levels (r = 0.8248 and 0.7474, respectively). Body weight index was statistically significantly associated with anti-RBD IgG levels (p = 0.035), while female recipients had higher anti-spike IgG levels (p = 0.038). The GMCs of NT50 declined with age (p = 0.0163) and were significantly different across age groups (159.7 IU/mL for 20-29 years, 99.4 IU/mL for ≥50 years, p = 0.0026). Injection-site pain, fever, and fatigue were the major reactogenicity, which were more pronounced after prime vaccination and in younger participants (<50 years). Platelet counts decreased and D-dimer levels increased after vaccination but were not clinically relevant. No serious adverse events or deaths were observed.

CONCLUSION:

The vaccine is well-tolerated and elicited robust humoral immunity against SARS-CoV-2 after standard prime-boost vaccination in Taiwanese recipients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10020312

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10020312